Brief: Aspira Women’s Health Inc Announces Agreement For The Development And Commercialization Of An Early-Detection Test For Identification Of Ovarian Cancer
25/03/2021 20:14
March 25 (Reuters) - Aspira Women's Health Inc AWH.O :
* ASPIRA WOMEN’S HEALTH, INC. ANNOUNCES AN AGREEMENT FOR THE
DEVELOPMENT AND COMMERCIALIZATION OF AN EARLY-DETECTION TEST FOR
IDENTIFICATION OF OVARIAN CANCER
* ASPIRA WOMEN'S HEALTH - ENTERED INTO AGREEMENT WITH
DANA-FARBER
CANCER INSTITUTE, BRIGHAM & WOMEN'S HOSPITAL, MEDICAL UNIVERSITY
LODZ
Source text for Eikon: ID:nGNX5LRSYd
Further company coverage: AWH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aspira Women's Health
See all newsBrief: Aspira Women’S Health Announces Receipt Of Delisting Notification From Nasdaq
Brief: Aspira Women's Health On April 4, Enters Equity Purchase Agreement With Triton Funds
Brief: Aspira Women's Health Files For Offering Up To 50 Units, 50 Mln Pre-Funded Units
Brief: Aspira Women's Health Interim CFO John Kallassy Resigns
Brief: Aspira Women's Health Fails To Regain Nasdaq Compliance